STAT3 and prostate cancer: Interestingly, we found that the MSC selected prostate cancer cells are also cross resistant to chemotherapies such as etoposide and docetaxel suggesting that STAT3 inhibition could be a viable route to resensitizing bone metastatic prostate cancer that is refractory to chemotherapy.